

Form 51-102F3
Material Change Report

1. Name and Address of Company

Restart Life Science Corp.

2. Dates of Material Change(s)

3. News Release(s)

4. Summaries of Material Changes

a

5. Full Description of Material Changes

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

7. Omitted Information

8. Executive Officer

9. Date of Report

Nova Mentis Life Sciences Corp. Announces Effective Date of Share Consolidation and Name Change

VANCOUVER, BC / November 5, 2024 / Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”) announces that, further to its news release dated October 31, 2024, the Company confirms the effective date for the consolidation of one (1) post-consolidation share for every five (5) pre-consolidation shares.

Effective at the opening on Friday, November 8, 2024, the shares of the Company will commence trading on the Canadian Securities Exchange on a consolidated basis under the name “Restart Life Sciences Corp.” and stock symbol “HEAL”.

Post-Consolidation Capitalization: Unlimited common shares with no par value of which approximately 29,663,732 common shares are issued and outstanding.

Transfer Agent: Olympia Trust Company

Trading Symbol: HEAL (new)

CUSIP Number: 76134J107 (new)

Record Date: November 8, 2024

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp (CSE: NOVA)(“NOVA” or the “Company”) a Canadian-based life sciences company listed on the Canadian Securities Exchange (“CSE”).

Nova Mentis Life Science Corp.
Steve Loutskou
Chief Executive Officer

FOR FURTHER INFORMATION, PLEASE VISIT:

www: www.novamentis.co or email info@novamentis.co
Tel:(778) 819-0244

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.